目的 探討金水寶膠囊聯(lián)合丙酸倍氯米松治療支氣管哮喘的有效性和安全性。方法 選取2016年4月-2017年4月哈爾濱醫(yī)科大學附屬第二醫(yī)院收治的支氣管哮喘患者149例，隨機分成對照組（74例）和治療組（75例）兩組。對照組患者吸入丙酸倍氯米松氣霧劑，50 μg/次，15~20 min內(nèi)吸入完畢，3次/d。治療組患者在對照組基礎(chǔ)上口服金水寶膠囊，3次/粒，3次/d。兩組患者均治療2周。觀察兩組患者臨床療效，同時比較治療前后兩組患者肺功能、炎癥因子水平和哮喘控制測試評分（ACT）評分。結(jié)果 治療后，對照組和治療組臨床總有效率分別為85.14%和96.00%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者一秒用力呼氣容積（FEV₁）、最大呼氣流量（PEF）、肺活量（VC）指標水平均顯著升高（P<0.05），且治療組患者上述肺功能明顯高于對照組（P<0.05）。治療后，兩組患者白細胞介素-4（IL-4）和腫瘤壞死因子-α（TNF-α）水平顯著降低（P<0.05），γ-干擾素（IFN-γ）顯著升高（P<0.05），同時治療后治療組上述炎癥因子水平明顯優(yōu)于對照組（P<0.05）。治療后，兩組患者ACT評分均顯著升高（P<0.05），且治療后治療組ACT評分明顯高于對照組（P<0.05）。結(jié)論 金水寶膠囊聯(lián)合丙酸倍氯米松治療支氣管哮喘療效好，肺功能改善明顯，具有一定的臨床推廣應用價值。

Objective To investigate the clinical efficacy and safety of Jinshuibao Capsules combined with beclomethasone dipropionate in treatment of bronchial asthma. Methods Patients (149 cases) with bronchial asthma in the 2nd Affiliated Hospital of Harbin Medical University from April 2016 to April 2017 were randomly divided into control (74 cases) and treatment (75 cases) groups. Patients in the control group were inhalation administered with Beclometasone Dipropionate Aerosol, 50 μg/time for 15-20 min, three times daily. Patients in the treatment group were po administered with Jinshuibao Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the lung function, the inflammatory factor levels, ACT scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 85.14% and 96.00% respectively, and there were differences between two groups (P<0.05). After treatment, the FEV1, PEF, and VC levels in two groups were significantly increased (P<0.05), and the lung function in the treatment group after treatment was significantly higher than that in the control group (P<0.05). After treatment, the IL-4 and TNF-α levels in two groups were significantly decreased (P<0.05), but IFN-γ levels were significantly increased (P<0.05), and the inflammatory factor levels in the treatment group after treatment were significantly better than those in the control group (P<0.05). After treatment, the ACT scores in two groups were significantly increased (P<0.05), and the ACT scores in the treatment group after treatment were significantly higher than those in the control group (P<0.05). Conclusion Jinshuibao Capsules combined with beclomethasone dipropionate in treatment of bronchial asthma has good curative effect on bronchial asthma, can obviously improve the lung function, which has a certain clinical application value.